Choden T, Mandaliya R, Charabaty A, Mattar MC. Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges. World J Gastrointest Pharmacol Ther 2018; 9(1): 1-7 [PMID: 29430322 DOI: 10.4292/wjgpt.v9.i1.1]
Corresponding Author of This Article
Mark C Mattar, MD, FACG, Division of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, DC 20007, United States. mark.c.mattar@gunet.georgetown.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pharmacol Ther. Feb 6, 2018; 9(1): 1-7 Published online Feb 6, 2018. doi: 10.4292/wjgpt.v9.i1.1
Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges
Tenzin Choden, Rohan Mandaliya, Aline Charabaty, Mark C Mattar
Tenzin Choden, Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC 20007, United States
Rohan Mandaliya, Aline Charabaty, Mark C Mattar, Division of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC 20007, United States
Author contributions: Choden T and Mandaliya R wrote the manuscript; Charabaty A and Mattar MC provided input on designing the outline and coordinated the writing of the paper.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Mark C Mattar, MD, FACG, Division of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, DC 20007, United States. mark.c.mattar@gunet.georgetown.edu
Telephone: +1-202-4441039 Fax: +1-877-3031462
Received: July 29, 2017 Peer-review started: July 30, 2017 First decision: September 6, 2017 Revised: October 13, 2017 Accepted: October 30, 2017 Article in press: October 30, 2017 Published online: February 6, 2018 Processing time: 187 Days and 12.1 Hours
Abstract
Inflammatory bowel disease has a high prevalence in women of childbearing age and can have a significant impact on pregnancy, from conceiving to carrying the pregnancy. Active disease during pregnancy is known to have negative effects on pregnancy outcomes; therefore, careful monitoring during this period is an important but challenging aspect of care and is crucial as it affects important management decisions. Recent data seems to suggest that endoscopy is a relatively safe procedure during all trimesters of pregnancy. Serum biomarkers such as C-reactive protein and fecal calprotectin are helpful non-invasive markers, but have shown conflicting results for correlation with disease activity in some initial studies. Further work is necessary to establish standard of care monitoring during pregnancy.
Core tip: This review article fills in the gap in the paucity of literature specifically focusing on the monitoring of inflammatory bowel disease during pregnancy. New and emerging literature on the use of non-invasive biomarkers such as fecal calprotectin is discussed, but classic monitoring techniques such as endoscopy and radiographic imaging are also evaluated within the scope of pregnancy.
